Invea Therapeutics Strengthens Leadership with Appointment of Dr. Stephen Doberstein, Veteran Biotech Executive, to Its Board of Directors
12. Dezember 2024 10:05 ET
|
Invea Therapeutics
GUILFORD, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Invea Therapeutics, Inc. (Invea), a leading biotechnology company developing an artificial intelligence (AI), GenAI, and machine learning (ML)...
GEn1E Lifesciences appoints François Nader, MD as Chair of its Board of Directors
11. Dezember 2024 07:01 ET
|
GEn1E Lifesciences Inc.
Dr. Nader, current Independent Board Director at Moderna and Senior Advisor at Blackstone Life Sciences, joins GEn1E Lifesciences board as chair.
Bionical Emas sells EMAS Pharma to Kester Capital following strategic review
09. Dezember 2024 02:00 ET
|
Bionical Emas
Bionical Emas, the Early Access Programs and Clinical Trial Supply business, is selling EMAS Pharma to Kester Capital and an incoming executive team.
Kester Capital backs experienced management team in acquiring EMAS Pharma
09. Dezember 2024 02:00 ET
|
EMAS Pharma
Kester Capital, alongside a new senior management team, has acquired EMAS Pharma, the clinical development division of Bionical Emas.
Derm-Biome Pharmaceuticals adds Dr. Jerry Tan, internationally renowned expert in acne and acne scarring, to its Scientific Advisory Board
25. November 2024 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company developing safe and highly effective topical treatments...
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
05. November 2024 07:00 ET
|
ZyVersa Therapeutics
Inflammasome-driven inflammation in obesity results in severely damaged pancreatic islets, leading to islet cell loss and metabolic dysfunction.
BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
17. Oktober 2024 08:07 ET
|
BioAegis Therapeutics
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
Attovia Therapeutics Appoints Chief Financial Officer
15. Oktober 2024 07:30 ET
|
Attovia Therapeutics, Inc.
FREMONT, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics announced the appointment of Steven Chan as Chief Financial Officer. Mr. Chan brings extensive financial strategy and...
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.
15. Oktober 2024 07:30 ET
|
Molecure
This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as...
Citryll and leading rheumatology centres receive Reumanederland grant to collaborate on NET research to advance novel treatments for rheumatoid arthritis.
03. Oktober 2024 02:00 ET
|
Citryll
CITRYLL AND LEADING RHEUMATOLOGY CENTRES RECEIVE REUMANEDERLAND GRANT TO COLLABORATE ON NET RESEARCH TO ADVANCE NOVEL TREATMENTS FOR RHEUMATOID ARTHRITIS Learnings will be used in the clinical...